135 related articles for article (PubMed ID: 37365217)
1. Analysis of survival and prognostic factors of clear cell adenocarcinoma of the prostate: a case-control study for a rare cancer entity.
Chen S; Song W; Zhang R; Jin Y; Lu Y; Lin L; Ye L; Li T; Wei Y
Sci Rep; 2023 Jun; 13(1):10317. PubMed ID: 37365217
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Survival Outcomes and Risk Factors Between Ductal Carcinoma of the Prostate and Acinar Adenocarcinoma of the Prostate: A Population-based Propensity Score-matching Study.
Wei Y; Kobayashi T; Lu Y; Vogel M; Zhang R; Wu J; Gao Y; Lin L; Zhu Q; Ye L; Horie S; Wang X; Li T
Eur Urol Open Sci; 2022 Dec; 46():88-95. PubMed ID: 36506256
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.
Yao J; Liu Y; Liang X; Shao J; Zhang Y; Yang J; Zheng M
Front Endocrinol (Lausanne); 2021; 12():778758. PubMed ID: 34956090
[TBL] [Abstract][Full Text] [Related]
4. Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?
Wu T; Zhao J; Liu Z; Shen P; Zhang M; Sun G; Liu J; Liao B; Chen J; Zhu S; Dai J; Wang Z; Zhang H; Zhao P; Zhang X; Zhu X; Ni Y; Chen N; Zeng H
Prostate; 2019 Oct; 79(14):1673-1682. PubMed ID: 31433509
[TBL] [Abstract][Full Text] [Related]
5. Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study.
Knipper S; Preisser F; Mazzone E; Mistretta FA; Tian Z; Briganti A; Zorn KC; Saad F; Tilki D; Graefen M; Karakiewicz PI
Clin Genitourin Cancer; 2019 Jun; 17(3):231-237.e2. PubMed ID: 31080021
[TBL] [Abstract][Full Text] [Related]
6. Effect of positive surgical margins at radical prostatectomy on cancer-specific mortality in high/very high-risk prostate cancer patients with Gleason Grade Group 4-5.
Panunzio A; Sorce G; Hoeh B; Hohenhorst L; Tappero S; Nimer N; Rajwa P; Tian Z; Terrone C; Chun FKH; Briganti A; Saad F; Shariat SF; Cerruto MA; Antonelli A; Karakiewicz PI
Prostate; 2023 Feb; 83(3):268-276. PubMed ID: 36336728
[TBL] [Abstract][Full Text] [Related]
7. Elderly patients aged ≥ 75 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis.
Sheng W; Kirschner-Hermanns R; Zhang H
World J Urol; 2019 Feb; 37(2):317-325. PubMed ID: 29951790
[TBL] [Abstract][Full Text] [Related]
8. Local Therapy Improves Survival in Metastatic Prostate Cancer.
Leyh-Bannurah SR; Gazdovich S; Budäus L; Zaffuto E; Briganti A; Abdollah F; Montorsi F; Schiffmann J; Menon M; Shariat SF; Fisch M; Chun F; Steuber T; Huland H; Graefen M; Karakiewicz PI
Eur Urol; 2017 Jul; 72(1):118-124. PubMed ID: 28385454
[TBL] [Abstract][Full Text] [Related]
9. Mucinous Prostate Cancer Shows Similar Prognosis to Typical Prostate Acinar Carcinoma: A Large Population-Based and Propensity Score-Matched Study.
Zhao F; Yu X; Xu M; Ye S; Zang S; Zhong W; Ren G; Chen X; Yan S
Front Oncol; 2019; 9():1467. PubMed ID: 31998638
[No Abstract] [Full Text] [Related]
10. Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients.
Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Fossati N; Gandaglia G; Gallina A; Abdollah F; Shariat SF; Montorsi F; Saad F; Tilki D; Briganti A; Karakiewicz PI
Eur Urol Focus; 2019 May; 5(3):381-388. PubMed ID: 29366856
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of clinicopathological characteristics and survival outcomes in prostate infiltrating ductal carcinoma: a population-based study.
Wu YP; Chen SH; Wang ST; Li XD; Cai H; Lin YZ; Xue XY; Wei Y; Zheng QS; Xu N
Oncotarget; 2017 Apr; 8(17):29048-29055. PubMed ID: 28423709
[TBL] [Abstract][Full Text] [Related]
12. Impact of surgical margin status on prostate-cancer-specific mortality.
Chalfin HJ; Dinizo M; Trock BJ; Feng Z; Partin AW; Walsh PC; Humphreys E; Han M
BJU Int; 2012 Dec; 110(11):1684-9. PubMed ID: 22788795
[TBL] [Abstract][Full Text] [Related]
13. Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate.
Packiam VT; Patel SG; Pariser JJ; Richards KA; Weiner AB; Paner GP; VanderWeele DJ; Zagaja GP; Eggener SE
Urology; 2015 Oct; 86(4):777-82. PubMed ID: 26196240
[TBL] [Abstract][Full Text] [Related]
14. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study.
Bandini M; Pompe RS; Marchioni M; Zaffuto E; Gandaglia G; Fossati N; Cindolo L; Montorsi F; Briganti A; Saad F; Karakiewicz PI
Int Urol Nephrol; 2018 Jan; 50(1):71-78. PubMed ID: 29129028
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy analysis of radiotherapy combined with surgery for locally advanced rectal mucinous adenocarcinoma: a retrospective study based on data of Surveillance, Epidemiology, and End results population].
Zhang Y; Wang X; Chi P; Lin H; Lu X; Huang Y; Xu Z; Huang S; Sun Y; Ye D
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):85-93. PubMed ID: 30703799
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of bladder neck involvement in non-muscle-invasive bladder cancer: A SEER database analysis with 19,919 patients.
Zhan X; Guo J; Chen L; Deng W; Liu X; Zhu K; Liu W; Fu B
Cancer Med; 2021 Oct; 10(19):6868-6880. PubMed ID: 34423585
[TBL] [Abstract][Full Text] [Related]
17. Survival after radical prostatectomy vs. radiation therapy in ductal carcinoma of the prostate.
Chierigo F; Borghesi M; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Höh B; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Montorsi F; Chun FKH; Shariat SF; Mantica G; Suardi N; Terrone C; Karakiewicz PI
Int Urol Nephrol; 2022 Jan; 54(1):89-95. PubMed ID: 34797483
[TBL] [Abstract][Full Text] [Related]
18. Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma.
Flammia RS; Chierigo F; Würnschimmel C; Horlemann B; Hoeh B; Sorce G; Tian Z; Leonardo C; Tilki D; Terrone C; Saad F; Shariat SF; Montorsi F; Chun FK; Gallucci M; Karakiewicz PI
Urol Oncol; 2022 Apr; 40(4):165.e9-165.e15. PubMed ID: 34686429
[TBL] [Abstract][Full Text] [Related]
19. How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer?
Jin K; Qiu S; Li J; Zheng X; Tu X; Liao X; Yang Y; Yang L; Wei Q
Cancer Med; 2019 Jul; 8(7):3370-3378. PubMed ID: 31066510
[TBL] [Abstract][Full Text] [Related]
20. Overall survival and cancer-specific survival were improved in local treatment of metastatic prostate cancer.
Miao Q; Wei Z; Liu C; Ye Y; Cheng G; Song Z; Chen K; Zhang Y; Chen J; Yue C; Ruan H; Zhang X
Front Oncol; 2023; 13():1130680. PubMed ID: 37207146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
